Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases ...

Ancora Heart has reached the first enrollment milestone in the CORCINCH-HF pivotal trial of the AccuCinch® System in patients with heart failure.

Heart failure with reduced ejection fraction (HFrEF) represents a significant global health burden, affecting over 64 million individuals and resulting in substantial morbidity and mortality, ...

Understand how MRI-derived RV strain predicts outcomes in HFpEF, offering improved risk stratification over traditional ...

Ancora Heart announced it has reached the first enrollment milestone in its CORCINCH-HF pivotal trial evaluating the ...

Presentation underscores unique potential for atrioventricular interval modulation ("AVIM”) therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction ...

CMR scans may reveal lamin heart disease prognostic biomarkers, enabling clinicians to better predict which patients are most ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in approval for deramiocel. Read more on CAPR stock here.